Transcript: Johnson & Johnson Q3 2026 Earnings Conference Call

Key takeaways

• J&J lifts 2026 revenue outlook to $100.7 billion and signals a strong path to $50 billion oncology sales by 2030, while legal costs and integration expenses weigh on earnings.
• Worldwide sales $25.4 billion (+6%)
• Adjusted net earnings $6.3 billion (-6.8%)
• Adjusted diluted EPS $2.59 (-7.5%)

What happened

Johnson & Johnson (JNJ) reported third‑quarter 2026 earnings that beat expectations, with worldwide sales of $25.4 billion, up 6% from a year earlier. Adjusted net earnings fell 6.8% to $6.3 billion, and adjusted diluted earnings per share dropped 7.5% to $2.59. The company raised its full‑year 2026 guidance to operational sales growth of 6.7%‑7.1% and projected annual revenue of $100.7 billion, the first time it will exceed $100 billion in a single year. Cash and securities stood at $17…

Why it matters

The higher revenue guidance signals stronger top‑line momentum and supports the company’s ambition to become the leading oncology firm by 2030. The cash position and debt profile give JNJ room to invest in growth initiatives and manage litigation costs. The earnings decline reflects one‑off legal expenses and…

Short-term and longer-term

Short-term. Over the next few days, watch for price reactions to the earnings release and the updated guidance.

Longer-term. Over the next few months, the company’s focus on oncology and psoriatic disease launches, combined with its strong cash position, positions J&J for sustained growth.